Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Conclusion: advances in current treatment for patients with newly diagnosed multiple myeloma

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME et al. Lenalidomide plus high dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open label randomised controlled trial. Lancet Oncol 2010; 11: 29–37.

    CAS  Article  Google Scholar 

  2. 2

    Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010; 376: 2075–2085.

    CAS  Article  Google Scholar 

  3. 3

    Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010; 28: 4621–4629.

    CAS  Article  Google Scholar 

  4. 4

    Sonneveld P, Schmidt-Wolf I, van der Holt B, el Jarari L, Bertsch U, Salwender H et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012; 30: 2946–2955.

    CAS  Article  Google Scholar 

  5. 5

    Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010; 116: 679–686.

    CAS  Article  Google Scholar 

  6. 6

    Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized trial. J Clin Oncol 2010; 28: 5101–5109.

    CAS  Article  Google Scholar 

  7. 7

    Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K et al. Improved progression free survival with bortezomib consolidation after high dose melphalan; results of a randomized phase III trial. Haematologica 2011; 96 (Suppl 1): (abstract O-11).

  8. 8

    Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010; 28: 2077–2084.

    CAS  Article  Google Scholar 

  9. 9

    Roussel M, Avet-Loiseau H, Moreau P, Huynh A, Benboubker L, Hulin C et al. Frontline therapy with bortezomib, lenalidomide, and dexamethasone (VRD) induction followed by autologous stem cell transplantation, VRD consolidation and lenalidomide maintenance in newly diagnosed multiple myeloma patients: primary results of the IFM 2008 phase II study. Blood 2010; 116: (abstract 624).

  10. 10

    Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010; 115: 1113–1120.

    CAS  Article  Google Scholar 

  11. 11

    Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021–1030.

    CAS  Article  Google Scholar 

  12. 12

    Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, Brown JM et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 2012; 119: 7–15.

    CAS  Article  Google Scholar 

  13. 13

    Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1782–1791.

    CAS  Article  Google Scholar 

  14. 14

    McCarthy PL, Owzar K, Anderson KC, Hofmeister CC, Hurd DD, Hassoun H et al. Lenalidomide after stem-cell transplantation in multiple myeloma. N Engl J Med 2012; 366: 1770–1781.

    CAS  Article  Google Scholar 

  15. 15

    Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. J Clin Oncol 2012; 366: 1759–1769.

    CAS  Google Scholar 

  16. 16

    Ishak J, Dimopoulos MA, Weber D, Knight RD, Shearer A, Caro JJ . Declining rates of adverse events and dose modifications with lenalidomide in combination with dexamethasone. Blood 2008; 112: (abstract 3708).

Download references


I thank Shanthi Jayawardena, PhD, and Eva Polk, PhD (Excerpta Medica), for the linguistic improvement of the manuscript. Editorial support in the preparation of this manuscript was funded by Celgene Corporation. SL is supported by the Richard and Annelly Deets Fund for Multiple Myeloma. SL was fully responsible for all content and editorial decisions for this manuscript.

Author information



Corresponding author

Correspondence to S Lonial.

Ethics declarations

Competing interests

SL has had a consultant role for Millennium, Celgene Corporation, Novartis, Merck, Bristol Myers Squibb, Onyx and Johnson and Johnson, with honoraria.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lonial, S. Conclusion: advances in current treatment for patients with newly diagnosed multiple myeloma. Leukemia Suppl 2, S28–S29 (2013).

Download citation


Quick links